Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HSPB1 | P04792 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307028 | 0.86 | PIN1 (0.65) | PIN1MAPTHSPB1HPGDSMN1; SMN2 | |
| SCHEMBL4910505 | 0.81 | CCR2 (0.48) | PIN1MAPTALDH1A1TDP1CCR2 | |
| SCHEMBL305881 | 0.80 | HTR1A (0.43) | MAPTLMNASMN1; SMN2HTR1ASLC6A2 | |
| SCHEMBL10222852 | 0.79 | PIN1 (0.43) | PIN1MAPTLMNAHPGDSMN1; SMN2 | |
| SCHEMBL4910462 | 0.76 | ALDH1A1 (0.55) | PIN1MAPTALDH1A1L3MBTL1GAA | |
| SCHEMBL8514116 | 0.76 | PIN1 (0.44) | PIN1MAPTLMNAHPGDSMN1; SMN2 | |
| SCHEMBL307928 | 0.75 | LMNA (0.50) | PIN1MAPTHSPB1LMNASMN1; SMN2 | |
| SCHEMBL1339022 | 0.75 | L3MBTL1 (0.65) | PIN1MAPTHSPB1HPGDSMN1; SMN2 | |
| SCHEMBL4903025 | 0.75 | MAPT (0.53) | PIN1MAPTHSPB1LMNASMN1; SMN2 | |
| SCHEMBL4912851 | 0.75 | CCR2 (0.54) | PIN1MAPTLMNAALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX INC (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2354126-B1 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX INC (US) | 2013-09-25 | — | — | EP | disclosed |
| US-8519135-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2474532-A1 | Heteroaryl sulfonamides and CCR2 | ChemoCentryx, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8093247-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2354126-A1 | Heteroaryl sulfonamides and CCR2 | ChemoCentryx, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-1838674-B1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX INC (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2008008431-A2 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-1838674-A2 | HETEROARYL SULFONAMIDES AND CCR2 | ChemoCentryx Inc (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. | 2006-08-03 | — | — | US | disclosed |
| WO-2006076644-A2 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173019-A1 | Heteroaryl sulfonamides and CCR2 | CCR2, CXCR2, CCR1 | PIN1 1021/4885MAPT 4602/4885HSPB1 1938/4885 |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | PIN1 850/4885MAPT 4586/4885HSPB1 2024/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | PIN1 1247/4885MAPT 4529/4885HSPB1 523/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | PIN1 850/4885MAPT 4586/4885HSPB1 2024/4885 |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CCR2, CXCR2, CCR1 | PIN1 1021/4885MAPT 4602/4885HSPB1 1938/4885 |
| US-20140031348-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | PIN1 850/4885MAPT 4586/4885HSPB1 2024/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | PIN1 850/4885MAPT 4586/4885HSPB1 2024/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | PIN1 850/4885MAPT 4586/4885HSPB1 2024/4885 |
| US-20110118248-A1 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | PIN1 850/4885MAPT 4586/4885HSPB1 2024/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | PIN1 850/4885MAPT 4586/4885HSPB1 2024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.